Tue, Dec 17, 2024
Volume 12, Issue 2 (Mar-Apr 2018)
mljgoums 2018, 12(2): 13-19 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
shahraki zahedani S, Javadi R. Evaluation of Antibiotic Resistance Patterns and Frequency of Carbapenemase-Producing Acinetobacter baumannii Isolates by the Carbacineto NP Test . mljgoums 2018; 12 (2) :13-19
URL: http://mlj.goums.ac.ir/article-1-1061-en.html
URL: http://mlj.goums.ac.ir/article-1-1061-en.html
1- Department of Microbiology, School of Medicine, Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
2- Department of Microbiology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran ,r.javadi3599@gmail.com
2- Department of Microbiology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran ,
Abstract: (15793 Views)
ABSTRACT
Background and Objectives: Acinetobacter baumannii is an opportunistic pathogen associated with nosocomial infections. Treatment of infections caused by this bacterium has become challenging due to increasing rate of resistance to a wide range of antibiotics such as carbapenems. One of the main mechanisms of resistance to carbapenems is the production of carbapenemase. The objective of this study was to evaluate antibiotic resistance patterns and frequency of carbapenemase-producing A. baumannii strains using the CarbAcineto NP Test.
Methods: In this descriptive cross-sectional study, 130 A. baumannii isolates were collected from clinical specimens of teaching hospitals in Zahedan in 2016. After determining the antibiotic resistance patterns, all A. baumannii isolates were examined using the phenotypic method of CarbAcineto NP test to evaluate production of carbapenemase enzymes.
Results: Based on the antibiogram results, more than 90% of the isolates were resistant to the antibiotics tested in this study. However, the lowest rate of resistance was observed against colistin, minocycline, tigecycline and doxycycline, respectively. Based on the results of the CarbAcineto NP test, 96% of carbapenem-resistant strains were positive for the production of carbapenemases.
Conclusion: Due to the high resistance of A. baumannii to carbapenems, they are not currently suitable for the treatment of infections caused by this bacterium. However, since most carbapenem-resistant strains are susceptible to colistin, minocycline, tigecycline, and doxycycline, these antibiotics or their combination are recommended for the treatment of the infections caused by the resistant strains. Rapid identification of carbapenemase-producing bacteria using efficient methods such as CarbAcineto NP test is essential to prevent their spread, particularly in hospitals.
KEYWORDS: Acinetobacter baumannii, Carbapenemase, CarbAcinetoNP Test.
Background and Objectives: Acinetobacter baumannii is an opportunistic pathogen associated with nosocomial infections. Treatment of infections caused by this bacterium has become challenging due to increasing rate of resistance to a wide range of antibiotics such as carbapenems. One of the main mechanisms of resistance to carbapenems is the production of carbapenemase. The objective of this study was to evaluate antibiotic resistance patterns and frequency of carbapenemase-producing A. baumannii strains using the CarbAcineto NP Test.
Methods: In this descriptive cross-sectional study, 130 A. baumannii isolates were collected from clinical specimens of teaching hospitals in Zahedan in 2016. After determining the antibiotic resistance patterns, all A. baumannii isolates were examined using the phenotypic method of CarbAcineto NP test to evaluate production of carbapenemase enzymes.
Results: Based on the antibiogram results, more than 90% of the isolates were resistant to the antibiotics tested in this study. However, the lowest rate of resistance was observed against colistin, minocycline, tigecycline and doxycycline, respectively. Based on the results of the CarbAcineto NP test, 96% of carbapenem-resistant strains were positive for the production of carbapenemases.
Conclusion: Due to the high resistance of A. baumannii to carbapenems, they are not currently suitable for the treatment of infections caused by this bacterium. However, since most carbapenem-resistant strains are susceptible to colistin, minocycline, tigecycline, and doxycycline, these antibiotics or their combination are recommended for the treatment of the infections caused by the resistant strains. Rapid identification of carbapenemase-producing bacteria using efficient methods such as CarbAcineto NP test is essential to prevent their spread, particularly in hospitals.
KEYWORDS: Acinetobacter baumannii, Carbapenemase, CarbAcinetoNP Test.
Research Article: Original Paper |
Received: 2018/03/14 | Accepted: 2018/03/14 | Published: 2018/03/14 | ePublished: 2018/03/14
Received: 2018/03/14 | Accepted: 2018/03/14 | Published: 2018/03/14 | ePublished: 2018/03/14
References
1. Nowak P, Paluchowska P. Acinetobacter baumannii: biology and drug resistance—role of carbapenemases. Folia Histochemica et Cytobiologica. 2016; 54(2): 61-74. doi: 10.5603/FHC.a2016.0009. [DOI:10.5603/FHC.a2016.0009]
2. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nature Reviews Microbiology. 2007; 5(12): 939-51. DOI:10.1038/nrmicro1789 [DOI:10.1038/nrmicro1789]
3. Richards A, Abu Kwaik Y, Lamont R. Code blue: Acinetobacter baumannii, a nosocomial pathogen with a role in the oral cavity. Molecular oral microbiology. 2015; 30(1): 2-15. [DOI:10.1111/omi.12072]
4. Espinal P, Marti S, Vila J. Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces. Journal of Hospital Infection. 2012; 80(1): 56-60. doi: 10.1016/j.jhin.2011.08.013. [DOI:10.1016/j.jhin.2011.08.013]
5. Da Silva GJ, Domingues S. Insights on the horizontal gene transfer of carbapenemase determinants in the opportunistic pathogen Acinetobacter baumannii. Microorganisms. 2016; 4(3): pii: E29. doi: 10.3390/microorganisms4030029. [DOI:10.3390/microorganisms4030029]
6. Dortet L, Poirel L, Errera C, Nordmann P. CarbAcineto NP test for rapid detection of carbapenemase-producing Acinetobacter spp. Journal of clinical microbiology. 2014; 52(7): 2359-64. doi: 10.1128/JCM.00594-14. [DOI:10.1128/JCM.00594-14]
7. Mahon CR, Manuselis G. Textbook of diagnostic microbiology. 5th ed. WB Saunders company; 2000. Jean B. Patel DA. M100 Performance Standards for Antimicrobial Susceptibility Testing. 27th Edition. Clinical and Laboratory Standards Institute. 2017; 224.
8. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. Journal of clinical microbiology. 2006; 44(8): 2974-6. doi: 10.1128/JCM.01021-06. [DOI:10.1128/JCM.01021-06]
9. Cherkaoui A, Emonet S, Renzi G, Schrenzel J. Characteristics of multidrug-resistant Acinetobacter baumannii strains isolated in Geneva during colonization or infection. Annals of clinical microbiology and antimicrobials. 2015; 14(1): 42. doi: 10.1186/s12941-015-0103-3 [DOI:10.1186/s12941-015-0103-3]
10. Liao C-H, Kung H-C, Hsu G-J, Lu P-L, Liu Y-C, Chen C-M, et al. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods. International journal of antimicrobial agents. 2008; 32 Suppl 3: S192-6. doi: 10.1016/S0924-8579(08)70027-X. [DOI:10.1016/S0924-8579(08)70027-X]
11. Kim UJ, Kim HK, An JH, Cho SK, Park K-H, Jang H-C. Update on the epidemiology, treatment, and outcomes of carbapenem-resistant Acinetobacter infections. Chonnam medical journal. 2014; 50(2): 37-44. doi: 10.4068/cmj.2014.50.2.37. [DOI:10.4068/cmj.2014.50.2.37]
12. Bonnin RA, Poirel L, Nordmann P. New Delhi metallo-β-lactamase-producing Acinetobacter baumannii: a novel paradigm for spreading antibiotic resistance genes. Future microbiology. 2014; 9(1): 33-41. doi: 10.2217/fmb.13.69. [DOI:10.2217/fmb.13.69]
13. Bonnin RA, Nordmann P, Poirel L. Screening and deciphering antibiotic resistance in Acinetobacter baumannii: a state of the art. Expert review of anti-infective therapy. 2013;11(6):571-83. doi: 10.1586/eri.13.38. [DOI:10.1586/eri.13.38]
14. Bonnin RA, Naas T, Poirel L, Nordmann P. Phenotypic, biochemical, and molecular techniques for detection of metallo-β-lactamase NDM in Acinetobacter baumannii. Journal of clinical microbiology. 2012; 50(4): 1419-21. doi: 10.1128/JCM.06276-11. [DOI:10.1128/JCM.06276-11]
15. Mohajeri P, Farahani A, Mehrabzadeh RS. Molecular Characterization of Multidrug Resistant Strains of Acinetobacter baumannii Isolated from Intensive Care Units in West of Iran. Journal of clinical and diagnostic research: JCDR. 2017; 11(2): DC20-DC22. doi: 10.7860/JCDR/2017/21156.9397. [DOI:10.7860/JCDR/2017/21156.9397]
16. Shoja S, Moosavian M, Rostami S, Farahani A, Peymani A, Ahmadi K, et al. Dissemination of carbapenem-resistant Acinetobacter baumannii in patients with burn injuries. Journal of the Chinese Medical Association. 2017; 80(4): 245-52. [DOI:10.1016/j.jcma.2016.10.013]
17. Adibhesami H, Douraghi M, Zeraati H, Bazmi F, Rahbar M, Pourmand MR, et al. Carbapenem-resistant Acinetobacter baumannii (CRAB) recovered from burn patients. Journal of Pharmacy & Pharmaceutical Sciences. 2016; 19(3): 339-48. doi: 10.18433/J3QK6M. [DOI:10.18433/J3QK6M]
18. Motamedifar M. Emergence of Multidrug Resistance and Metallo‑beta‑lactamase Producing Acinetobacter baumannii Isolated from Patients in Shiraz, Iran. Annals. 2016; 6(3): 162-167. doi: 10.4103/2141-9248.183946. [DOI:10.4103/2141-9248.183946]
19. Dahdouh E, Gómez-Gil R, Pacho S, Mingorance J, Daoud Z, Suárez M. Clonality, virulence determinants, and profiles of resistance of clinical Acinetobacter baumannii isolates obtained from a Spanish hospital. PloS one. 2017; 12(4): e0176824. doi: 10.1371/journal.pone.0176824. [DOI:10.1371/journal.pone.0176824]
20. Agarwal S, Kakati B, Khanduri S, Gupta S. Emergence of Carbapenem Resistant Non-Fermenting Gram-Negative Bacilli Isolated in an ICu of a Tertiary Care Hospital. Journal of clinical and diagnostic research: JCDR. 2017;11(1):DC04-07. doi: 10.7860/JCDR/2017/24023.9317. [DOI:10.7860/JCDR/2017/24023.9317]
21. Kim D, Ahn JY, Lee CH, Jang SJ, Lee H, Yong D, et al. Increasing Resistance to Extended-Spectrum Cephalosporins, Fluoroquinolone, and Carbapenem in Gram-Negative Bacilli and the Emergence of Carbapenem Non-Susceptibility in Klebsiella pneumoniae: Analysis of Korean Antimicrobial Resistance Monitoring System. Annals of laboratory medicine. 2017; 37(3): 231-9. doi: 10.3343/alm.2017.37.3.231. [DOI:10.3343/alm.2017.37.3.231]
22. Warner WA, Kuang SN, Hernandez R, Chong MC, Ewing PJ, Fleischer J, et al. Molecular characterization and antimicrobial susceptibility of Acinetobacter baumannii isolates obtained from two hospital outbreaks in Los Angeles County, California, USA. BMC infectious diseases. 2016; 16(1): 194. doi: 10.1186/s12879-016-1526-y. [DOI:10.1186/s12879-016-1526-y]
23. Adibhesami H, Douraghi M, Rahbar M, Abdollahi A. Minocycline activity against clinical isolates of multidrug-resistant Acinetobacter baumannii. Clinical Microbiology and Infection. 2015;21(11):e79-e80. doi: 10.1016/j.cmi.2015.07.007. [DOI:10.1016/j.cmi.2015.07.007]
24. Lashinsky JN, Henig O, Pogue JM, Kaye KS. Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A baumannii: A Review. Infectious diseases and therapy. 2017; 6(2): 199-211. doi: 10.1007/s40121-017-0153-2. [DOI:10.1007/s40121-017-0153-2]
25. Denys GA, Callister SM, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Annals of clinical microbiology and antimicrobials. 2013;12(1):24. [DOI:10.1186/1476-0711-12-24]
26. Gao L, Lyu Y, Li Y. Trends in Drug Resistance of Acinetobacter baumannii over a 10-year Period: Nationwide Data from the China Surveillance of Antimicrobial Resistance Program. Chinese Medical Journal. 2017; 130(6): 659. [DOI:10.4103/0366-6999.201601]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.